Esperion's LDL med aces a third pivotal trial

In its third pivotal trial readout this year, the 180-mg dose of Esperion's LDL cholesterol-lowering treatment, bempedoic acid, hit its primary endpoint in a trial of high-risk patients with atherosclerotic cardiovascular disease (ASCVD). And there is more to come—the company expects to report data from two more studies later this year.